Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tables, pellets, capsules, granules and powders.  The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.

Recent Press Releases:

3/22/2012	ELITE PHARMACEUTICALS SIGNS AN AGREEMENT WITH A PRIVATE HONG KONG-BASED COMPANY TO DEVELOP A PRESCRIPTION PHARMACEUTICAL PRODUCT IN THE US
3/13/2012	ELITE PHARMACEUTICALS ANNOUNCES FIRST SHIPMENT OF GENERIC HYDROMORPHONE PRODUCT
2/13/2012	Elite Pharmaceuticals, Inc. to Discuss Third Quarter 2012 Results of Operations on Wednesday, February 15, 2012
1/26/2012	ELITE PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL APPLICATION FOR HYDROMORPHONE
1/3/2012	ELITE PHARMACEUTICALS SECURES $5 MILLION FUNDING COMMITMENT